Multiple sclerosis in the Levant: a regional consensus statement.

The epidemiology of multiple sclerosis (MS) is rapidly changing in many parts of the world. In a geographic area that was previously associated with low prevalence, recent studies showing high prevalence and fast rising incidence of MS in the Levant countries led us neurologists of this region to meet in a consensus panel, in order to share our latest findings in terms of MS epidemiology and consent on MS management in the Levant. Twelve neurologists and MS experts representing various countries of the Levant (Lebanon, Syria, Jordan and Iraq) have met in Beirut on the 17(th) of February 2013, shared their latest epidemiological findings, discussed recent MS aspects in the region, and drafted a consensus on MS management relevant to this geographic area.

Expert opinion on the pharmacological management of multiple sclerosis in women of childbearing age in Iraq.

Background: Multiple sclerosis (MS) is often diagnosed in women of childbearing age (WCBA), with a mean age of onset of 30 years. Women with MS have long been cautioned to carefully plan their pregnancies and, traditionally, disease-modifying therapies (DMTs) have not been recommended for use in patients engaged in family planning. In 2020, the United States Food and Drug Administration (FDA) approved a label update for interferon beta (IFN ß) by adding new safety data on pregnancy and breastfeeding. Because current management guidelines do not yet reflect the recent label update, a panel of neurology experts from Iraq decided to discuss the potential need for changes in treatment strategies in Iraq. Methods: A panel of experts consisting of 8 neurologists from Iraq and one international neurology expert from Germany convened to develop an expert opinion that would provide practical guidance for the pharmacological management of WCBA with MS in Iraq. They considered the latest label update and relevant published literature, along with local clinical practice and available resources. Results: Interferon and Glatiramer acetate have no evidence of harm during pregnancy. IFN ß can be continued safely through pregnancy. Switching treatment during pregnancy is generally not recommended. Short-term intravenous methylprednisolone can be used to treat disabling relapses. Conclusion: Given the complexity of managing MS in pregnant women, it is the opinion of the expert panel that family planning should be discussed early in the disease course, planned pregnancy should be encouraged, and open communication with patient for her treatment decisions is paramount. Patients who are engaged in family planning are no longer discouraged from treatment with some of the currently available DMTs.

Association of Chlamydia pneumoniae serology and ischemic stroke.

BACKGROUND: Stroke is one of the major causes of morbidity and mortality throughout the world. Reports about the role of Chlamydia pneumoniae infection in the development of atherosclerosis have been reported in many studies. The aim of the study was to evaluate the association between Chlamydia pneumoniae infection and ischemic stroke. METHODS: We evaluated 50 patients with ischemic stroke (32 males and 18 females) and 40 control subjects (22 males and 18 females). They were age- and sex-matched. All enrolled subjects underwent an enzyme-linked immunosorbent assay (ELISA) serologic test for IgG and IgA antibodies for Chlamydia pneumoniae. RESULTS: Eighteen (36%) patients with ischemic stroke have positive IgA, in comparison with 6 (15%) among the control group (OR 3.18; CI 1.12-9.04; P = 0.03). This translates into the fact that there was a more than three-fold risk of developing ischemic stroke in those with Chlamydia pneumoniae infection compared to those who without. The IgG seropositivity was increased in patients with ischemic stroke, but it did not reach statistical significance (OR = 2.32; CI = 0.97-5.58; P = 0.078). CONCLUSIONS: Chronic Chlamydia pneumoniae infection demonstrated by positive IgA-type antibody can be considered a significant risk for ischemic stroke.

Hypertension as a risk factor: is it different in ischemic stroke and acute myocardial infarction comparative cross-sectional study?

Objective. To assess differences in age of onset, hypertension duration, type of drug, treatment compliance, and salt-free diet compliance between patients with stroke and myocardial infarction. Patients and Methods. The study was conducted in 3 hospitals in Baghdad between June 2010 and June 2011. First group includes 81 stroke patients (36 females and 45 males), age ranges between (33-82 years). Second group includes 110 myocardial infarction patients (46 females and 64 males), ages ranges from (23-76 years). Results. Salt-free diet noncompliance was seen in 69% and 62% of Myocardial infarction and stroke groups, respectively. Silent hypertension was seen in 6.3% and 19.7% of myocardial infarction and stroke groups, respectively. Noncompliant on antihypertensive therapy was seen in 61%, 71%, and 48% of the total, myocardial infarction, and stroke groups, respectively. The drug type was 24% angiotensin converting enzyme inhibitor, 18.8% combined drugs, 16.2% Beta Blocker, 11% angiotensin 11 receptor blocker, 10.4% calcium channel blocker and 7.3% diuretic. In stroke group, the commonest drug was 23% angiotensin converting inhibitor and the least (5%) was angiotensin receptor blocker. In myocardial infarction group, the commonest drug was 25% Angiotensin Converting Inhibitor and the least (8%) was diuretic. Discussion and Conclusion. Silent hypertension was high in Iraq. Salt-free diet noncompliance was high in both groups; drug noncompliance was significantly higher in patients with myocardial infarction. Angiotensin 11 receptor blocker use was associated significantly with myocardial infarction more than in stroke.